GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Total Assets

Roquefort Therapeutics (LSE:ROQ) Total Assets : £6.07 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Total Assets?

Roquefort Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was £6.07 Mil.

During the past 12 months, Roquefort Therapeutics's average Total Assets Growth Rate was -4.60% per year.

Total Assets is connected with ROA %. Roquefort Therapeutics's annualized ROA % for the quarter that ended in Jun. 2024 was -19.04%. Total Assets is also linked to Revenue through Asset Turnover. Roquefort Therapeutics's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.


Roquefort Therapeutics Total Assets Historical Data

The historical data trend for Roquefort Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Total Assets Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Assets
4.56 7.77 6.09

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Assets Get a 7-Day Free Trial 4.76 7.77 7.12 6.09 6.07

Roquefort Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Roquefort Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=5.5+0.589
=6.09

Roquefort Therapeutics's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets=Total Equity (Q: Jun. 2024 )+Total Liabilities (Q: Jun. 2024 )
=4.929+1.145
=6.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roquefort Therapeutics  (LSE:ROQ) Total Assets Explanation

Total Assets is connected with ROA %.

Roquefort Therapeutics's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=-1.158/( (6.089+6.074)/ 2 )
=-1.158/6.0815
=-19.04 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Roquefort Therapeutics's Asset Turnover for the quarter that ended in Jun. 2024 is

Asset Turnover
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (6.089+6.074)/ 2 )
=0/6.0815
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Roquefort Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines